The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.